Remission-driven discontinuation shapes the observed duration of emicizumab in acquired hemophilia A. Comment on: “Short-term emicizumab in patients with acquired hemophilia A”

We only have this paper's title and publication details.

Commentary highlights remission-driven discontinuation as a primary determinant of emicizumab treatment duration in acquired hemophilia A, suggesting shorter courses reflect disease resolution.